BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 25981685)

  • 1. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
    Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
    Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man.
    Gotter AL; Forman MS; Harrell CM; Stevens J; Svetnik V; Yee KL; Li X; Roecker AJ; Fox SV; Tannenbaum PL; Garson SL; Lepeleire ID; Calder N; Rosen L; Struyk A; Coleman PJ; Herring WJ; Renger JJ; Winrow CJ
    Sci Rep; 2016 Jun; 6():27147. PubMed ID: 27256922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis.
    Rappas M; Ali AAE; Bennett KA; Brown JD; Bucknell SJ; Congreve M; Cooke RM; Cseke G; de Graaf C; Doré AS; Errey JC; Jazayeri A; Marshall FH; Mason JS; Mould R; Patel JC; Tehan BG; Weir M; Christopher JA
    J Med Chem; 2020 Feb; 63(4):1528-1543. PubMed ID: 31860301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical usefulness of dual orexin receptor antagonism beyond insomnia: Neurological and psychiatric comorbidities.
    Carpi M; Palagini L; Fernandes M; Calvello C; Geoffroy PA; Miniati M; Pini S; Gemignani A; Mercuri NB; Liguori C
    Neuropharmacology; 2024 Mar; 245():109815. PubMed ID: 38114045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orexin, Sleep, Sympathetic Neural Activity, and Cardiovascular Function.
    Bigalke JA; Shan Z; Carter JR
    Hypertension; 2022 Dec; 79(12):2643-2655. PubMed ID: 36148653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Characterization of Cannabidiol as an OX1R Antagonist by Computational and In Vitro Functional Validation.
    Vitale RM; Iannotti FA; Schiano Moriello A; Tunisi L; Piscitelli F; Savopoulos R; Cristino L; De Petrocellis L; Amodeo P; Gray R; Di Marzo V
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights on the potential effect of orexin receptor antagonist suvorexant on Parkinson's disease symptoms.
    Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Saad HM; Batiha GE
    Neurol Sci; 2024 May; 45(5):2367-2368. PubMed ID: 38231375
    [No Abstract]   [Full Text] [Related]  

  • 8. Orexin antagonists for insomnia.
    Young J; Lee E; Lindblad AJ; Falk J
    Can Fam Physician; 2024 Mar; 70(3):183-184. PubMed ID: 38499379
    [No Abstract]   [Full Text] [Related]  

  • 9. Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia.
    Konno Y; Kamigaso S; Toki H; Terasaka S; Hikichi H; Endo H; Yamaguchi JI; Mizuno-Yasuhira A
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1183. PubMed ID: 38491717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.
    Brotschi C; Bolli MH; Gatfield J; Roch C; Sifferlen T; Treiber A; Williams JT; Boss C
    RSC Med Chem; 2024 Jan; 15(1):344-354. PubMed ID: 38283232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmentation With Dual Orexin Receptor Antagonist for Sundown Syndrome.
    Li YW; Yeh TC
    Am J Ther; 2023 Sep-Oct 01; 30(5):e459-e461. PubMed ID: 37713693
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel orexin receptor agonists based on arene- or pyridine-fused 1,3-dihydro-2H-imidazole-2-imines.
    Wang W; Ranjan A; Zhang W; Liang Q; MacMillan KS; Chapman K; Wang X; Chandrasekaran P; Williams NS; Rosenbaum DM; De Brabander JK
    Bioorg Med Chem Lett; 2024 Feb; 99():129624. PubMed ID: 38272190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-Step Regio- and Stereoselective Electrochemical Synthesis of Orexin Receptor Antagonist Oxidative Metabolites.
    Yao H; Sherer EC; Lu M; Small J; Martin GE; Lam YH; Chen Q; Helmy R; Liu Y; Chen H
    J Org Chem; 2022 Nov; 87(22):15011-15021. PubMed ID: 36322780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent trends in orexin research--2010 to 2015.
    Boss C; Roch C
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2875-87. PubMed ID: 26045032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers.
    Vermeeren A; Sun H; Vuurman EF; Jongen S; Van Leeuwen CJ; Van Oers AC; Palcza J; Li X; Laethem T; Heirman I; Bautmans A; Troyer MD; Wrishko R; McCrea J
    Sleep; 2015 Nov; 38(11):1803-13. PubMed ID: 26039969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Vitro and In Vivo Evidence for Active Brain Uptake of the GHB Analog HOCPCA by the Monocarboxylate Transporter Subtype 1.
    Thiesen L; Kehler J; Clausen RP; Frølund B; Bundgaard C; Wellendorph P
    J Pharmacol Exp Ther; 2015 Aug; 354(2):166-74. PubMed ID: 25986445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice.
    Morooka S; Hoshina M; Kii I; Okabe T; Kojima H; Inoue N; Okuno Y; Denawa M; Yoshida S; Fukuhara J; Ninomiya K; Ikura T; Furuya T; Nagano T; Noda K; Ishida S; Hosoya T; Ito N; Yoshimura N; Hagiwara M
    Mol Pharmacol; 2015 Aug; 88(2):316-25. PubMed ID: 25993998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
    Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a randomized, 6-week sleep laboratory trial.
    Ivgy-May N; Ruwe F; Krystal A; Roth T
    Sleep Med; 2015 Jul; 16(7):838-44. PubMed ID: 26047892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
    Ivgy-May N; Roth T; Ruwe F; Walsh J
    Sleep Med; 2015 Jul; 16(7):831-7. PubMed ID: 26047890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.